irinotecan has been researched along with rrx-001 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caroen, S; Carter, C; Cho-Phan, C; Fanger, G; Fisher, G; Knox, S; Kunz, P; Ning, S; Oronsky, B; Parker, C; Reid, T; Scicinski, J | 1 |
| Cabrales, P; Oronsky, B; Reid, T | 1 |
1 trial(s) available for irinotecan and rrx-001
| Article | Year |
|---|---|
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Nitro Compounds; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Pyridines; Survival Rate | 2015 |
1 other study(ies) available for irinotecan and rrx-001
| Article | Year |
|---|---|
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Brain Neoplasms; Cell Line, Tumor; Female; Glioma; Humans; Irinotecan; Mice; Mice, Nude; Nitro Compounds; Temozolomide; Xenograft Model Antitumor Assays | 2021 |